Zacks Investment Research
20 Feb 2026, 16:01 UTC · 32w ago
Pediatrix Medical Q4 Earnings Miss Estimates Despite Declining Costs
Impact · against what's priced in
Pediatrix Medical Group's stock is likely to face downward pressure following misses on both quarterly and annual adjusted EPS. While operational efficiency is improving via a 23% increase in adjusted EBITDA and lower operating expenses, these gains were insufficient to offset weakening organic growth and higher incentive compensation.
- MD−0.30
No priced-in read yet
- In context
The company missed Q4 adjusted EPS estimates by 4.9% and annual adjusted EPS by $0.03, while same-unit revenue growth of 4% fell short of the 6.8% consensus.
Read from the article alone
Search tags
